JonesResearch downgraded Lantheus (LNTH) to Hold from Buy without a price target following the Q4 report. The company is focusing on its radiodiagnostic portfolio while seeking strategic alternatives for its radiotherapeutic assets, the analyst tells investors in a research note. The firm sees potential for short-term positive stock moves following favorable regulatory decisions, but says these assets are not expected to substantially contribute to Lantheus’ fiscal 2026 revenue. As such, Jones finds the stock appropriately valued.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LNTH:
- Lantheus price target raised to $85 from $75 at TD Cowen
- Lantheus: Resilient Pylarify Performance and Cash Generation Underpin Buy Rating Despite Near‑Term Pricing Headwinds
- Lantheus upgraded to Outperform from Market Perform at William Blair
- William Blair upgrades Lantheus to Outperform on expected return to growth
- Lantheus reports Q4 adjusted EPS $1.67, consensus $1.17